SMARCA4 mutations in carcinomas of the esophagus, esophagogastric junction, and stomach.

[1]  L. Macconaill,et al.  Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: first two cases with clinicopathologic and molecular comparison to eight visceral counterparts , 2022, Modern Pathology.

[2]  R. Kurzrock,et al.  SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy , 2021, Molecular Cancer Therapeutics.

[3]  A. Agaimy,et al.  Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas , 2021, Cancers.

[4]  R. Petty,et al.  Best supportive care and prognosis: advanced gastroesophageal adenocarcinoma , 2021, BMJ supportive & palliative care.

[5]  Benjamin E. Gross,et al.  OncoTree: A Cancer Classification System for Precision Oncology. , 2021, JCO clinical cancer informatics.

[6]  F. Setién,et al.  SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade , 2020, Nature Communications.

[7]  E. Sokol,et al.  Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients , 2020, Nature Communications.

[8]  Jian Wang,et al.  Primary SMARCA4-deficient undifferentiated sarcomatoid tumor of the gastroesophageal junction , 2020 .

[9]  J. Goldblum,et al.  SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction. , 2020, The American journal of surgical pathology.

[10]  B. Taylor,et al.  The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer , 2020, Clinical Cancer Research.

[11]  K. Magliocca,et al.  Recurrent Loss of SMARCA4 in Sinonasal Teratocarcinosarcoma , 2020, The American journal of surgical pathology.

[12]  T. Kohno,et al.  SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma , 2020, NAR cancer.

[13]  T. Yeh,et al.  The clinicopathological and molecular analysis of gastric cancer with altered SMARCA4 expression , 2020, Histopathology.

[14]  J. Bishop,et al.  SMARCA4-deficient Sinonasal Carcinoma , 2020, The American journal of surgical pathology.

[15]  T. Zander,et al.  Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma , 2020, BMC Cancer.

[16]  David R. Jones,et al.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  S. Pambuccian,et al.  A BAFfling liver aspirate: Metastatic high grade SMARCA4 deficient undifferentiated gastroesophageal junction carcinoma masquerading as a hematolymphoid malignancy , 2019, Diagnostic cytopathology.

[18]  L. Zhu,et al.  trackViewer: a Bioconductor package for interactive and integrative visualization of multi-omics data , 2019, Nature Methods.

[19]  L. Macconaill,et al.  Targeted Cancer Next-Generation Sequencing as a Primary Screening Tool for Microsatellite Instability and Lynch Syndrome in Upper Gastrointestinal Tract Cancers , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[20]  William A. Pastor,et al.  SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer , 2019, Nature Communications.

[21]  L. Macconaill,et al.  Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma , 2018, Modern Pathology.

[22]  L. Macconaill,et al.  SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma , 2018, Modern Pathology.

[23]  Wai Lim Ku,et al.  Dominant-negative SMARCA4 missense mutations alter the accessibility landscape of tissue-unrestricted enhancers , 2017, Nature Structural & Molecular Biology.

[24]  A. Hartmann,et al.  SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg/CK7pos/HepPar-1pos immunophenotype , 2017, Virchows Archiv.

[25]  L. Macconaill,et al.  Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. , 2017, Archives of pathology & laboratory medicine.

[26]  T. Kohno,et al.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities , 2017, Modern Pathology.

[27]  Wai Lim Ku,et al.  Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin , 2016, Nature Genetics.

[28]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[29]  N. Girard,et al.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[31]  N. Schultz,et al.  Recurrent SMARCA4 mutations in small cell carcinoma of the ovary , 2014, Nature Genetics.

[32]  R. Siebert,et al.  Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type , 2014, Nature Genetics.

[33]  W. Foulkes,et al.  Familial rhabdoid tumour 'avant la lettre'—from pathology review to exome sequencing and back again , 2013, The Journal of pathology.

[34]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[35]  M. Sanchez-Cespedes,et al.  Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer , 2008, Epigenetics.

[36]  P. F. Tauber,et al.  Immature teratomas of different origin carried by a pregnant mother and her fetus. , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.